Brief: Allergy Therapeutics Enters Final Phase Of Treatment In Phase I/IIA VLP Peanut Protect Trial
27/03/2025 07:43
March 27 (Reuters) - Allergy Therapeutics PLC AGY.L: ALLERGY THERAPEUTICS PLC: ADVANCES TO FINAL PHASE OF TREATMENT IN PHASE I/IIA VLP PEANUT PROTECT TRIAL Source text: ID:nRSa3873Ca Further company coverage: AGY.L ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Allergy Therapeutics
See all newsBrief: Allergy Therapeutics Expects FY 2026 Revenue Of £59.90 Million, Up 9% Reported
UK's Allergy Therapeutics FY revenue beats on Grassmuno launch
Allergy Therapeutics - Trading update for the year ended 30 June 2026
Brief: Allergy Therapeutics Appoints Helge Weiner-Trapness As Executive Chairman
Allergy Therapeutics - Appointment of Executive Chairman